Abstract

While the exploitation of the Sharpless asymmetric dihydroxylation as the source of chirality in the synthesis of acyclic molecules and saturated heterocycles has been tremendous, its synthetic utility toward chiral benzo-annulated heterocycles is relatively limited. Thus, in the search for wider applications of Sharpless asymmetric dihydroxylation-derived diols for the synthesis of benzo-annulated heterocycles, we report herein our studies in the asymmetric synthesis of (R)-1-((R)-6-fluorochroman-2-yl)ethane-1,2-diol, (R)-1-((S)-6-fluorochroman-2-yl)ethane-1,2-diol and (S)-6-fluoro-2-((R)-oxiran-2-yl)chroman, which have been used as late-stage intermediates for the asymmetric synthesis of the antihypertensive drug (S,R,R,R)-nebivolol. Noteworthy is that a large number of racemic and asymmetric syntheses of nebivolol and their intermediates have been described in the literature, however, the Sharpless asymmetric dihydroxylation has never been employed as the sole source of chirality for this purpose.

Highlights

  • A number of syntheses of nebivolol and its intermediates have been described in the literature [10,11,12,13,14,15,16,17,18,19]

  • Nebivolol (1, Figure 1) is a chroman-based antihypertensive drug that was first reported in the racemic form [2,3]

  • For the synthesis of chroman derivative 2, first a base-mediated intramolecular SNAr reaction was envisioned for the aryl C–O bond formation under transition-metal-free conditions [28,29,30]

Read more

Summary

Introduction

A number of syntheses of nebivolol and its intermediates have been described in the literature [10,11,12,13,14,15,16,17,18,19]. The intramolecular ring-opening of enantiomerically pure epoxides by the phenolic hydroxy group is one of the most popular methods to construct 3 (Scheme 1, method 1). (obtained by intramolecular epoxide ring-opening of 8 which is the enantiomer of 6) has been followed to obtain 2 (Scheme 1, method 3) whereupon the overall yield of the reaction sequence diminished [11].

Results
Conclusion
Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.